Research programme: proto oncogene proteins c-akt inhibitors - Astex/Institute of Cancer Research/Cancer Research TechnologyAlternative Names: AT 11854; AT 7867; CCT 128930; CCT 129254; CCT077373; CCT077933
Latest Information Update: 16 Oct 2013
At a glance
- Originator Astex Therapeutics; Cancer Research UK; The Institute of Cancer Research
- Developer Astex Pharmaceuticals; Cancer Research UK; The Institute of Cancer Research
- Class Benzamides; Piperidines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors; Rho-associated kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer